Does Medicaid Cover Weight Loss Drugs? 1990 to Now

Does Medicaid cover weight loss drugs? Sometimes. States can choose to cover them, but federal law lets states exclude medicines used for weight loss. Coverage also depends on why the medicine was prescribed. Diabetes treatment follows a different rule.

That split reaches back to a law signed on Monday, November 5, 1990. It created Medicaid's national drug rebate program. The explicit words “weight loss” arrived in a 1993 rewrite. Those two dates help explain why today's answer changes across state lines.

November 5, 1990: the document behind the rule

The printed law carries its own dateline: “PUBLIC LAW 101-508—NOV. 5, 1990.” Its name was the Omnibus Budget Reconciliation Act of 1990, usually shortened to OBRA 1990.

Section 4401 added Section 1927 to the Social Security Act. That section set up manufacturer rebates, money returned to Medicaid after prescriptions were paid for.

The original exclusion list, at 104 Stat. 1388-149, began: “Agents when used for anorexia or weight gain.” Anorexia means loss of appetite. The familiar longer wording came later.

The day before: no national rebate requirement

Before this law, Medicaid lacked the nationwide manufacturer rebate requirement that became central to its drug benefit. Some states already had rebate agreements. The law itself recognized qualifying existing agreements, so the starting point wasn't an absence of every discount.

The Congressional Research Service's report on Medicaid drug pricing, updated November 7, 2014, says the 1990 law “established the Medicaid drug rebate program, which assured Medicaid programs would receive the best price.” States would share those savings with the federal government, which helps fund the program.

What the 1990 law changed

The bargain connected broad drug coverage with manufacturer refunds. A manufacturer entered a rebate agreement, and states generally covered its qualifying outpatient medicines, those dispensed outside a hospital stay. The rebate requirement first applied to drugs dispensed on or after January 1, 1991.

But the same law also set out a list of uses states could exclude or restrict. It included the appetite-and-weight provision, fertility treatment and cosmetic uses. Permission to exclude was a state choice, rather than a requirement to refuse every prescription in those groups.

That helps explain a distinction someone prescribed tirzepatide encounters today. A clinician can find a medicine appropriate while the payer excludes the reason it is being prescribed. Medical suitability and payment are separate decisions.

What happened next, from 1993 to 2025

1993: weight loss became explicit. Congress rewrote the coverage section. The enrolled 1993 act, Section 13602, used the wording still familiar today: “Agents when used for anorexia, weight loss, or weight gain.” The current U.S. Code records that rewrite. The framework dates to 1990; this exact phrase dates to 1993.

2003: Medicare borrowed the list. The law creating Part D, Medicare's prescription-drug benefit, incorporated most of Medicaid's optional exclusions, including the weight-loss category; the separate Medicare GLP-1 Bridge is explained in our Medicare GLP-1 coverage guide.

2021 and 2023: newer medicines met an older rule. Wegovy, containing semaglutide, received approval from the U.S. Food and Drug Administration (FDA) on June 4, 2021, and Zepbound, containing tirzepatide, followed on November 8, 2023; those approvals cover the branded products rather than compounded versions. Both entered a system where weight-loss coverage remained optional. GLP-1 medicines act on a gut-hormone signal involved in appetite and blood sugar.

2024: researchers documented the gap. A JAMA study by Liu and Rome found that about 1 in 5 states reviewed, 10 of 47, covered an obesity medicine in early 2023. That count covered obesity medicines generally, rather than GLP-1s alone.

A separate 2024 study in Diabetes, Obesity and Metabolism examined records of 50,678 adults with obesity in one large health system in Ohio and Florida. Medicaid insurance was associated with lower chances of receiving and filling an obesity-drug prescription than private insurance. It did not establish that the 1990 law caused those differences.

2025: a new pricing agreement. The November 6 White House announcement included Medicaid terms in agreements with Lilly and Novo Nordisk; the separate TrumpRx guide explains the consumer cash route.

Medicaid GLP-1 coverage in 2026

As of October 29, 2026, the day this article was written, KFF's analysis, published January 16, 2026, counted 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026. Fee-for-service means the program pays providers directly. California, New Hampshire, Pennsylvania and South Carolina had ended that coverage; North Carolina had restored it. State rules have changed since then, as Rhode Island's shows.

As of October 29, 2026, the day this article was written, CMS's BALANCE page, marked “Page Last Modified: 09/29/2026 02:17 PM,” allows states to join from May 2026 through January 1, 2027. BALANCE is a voluntary program combining negotiated drug terms with lifestyle support. Coverage depends on state and manufacturer participation, plus individual eligibility.

As of October 29, 2026, the day this article was written, Rhode Island's August 5, 2026 memorandum set October 1, 2026 as the date its Medicaid program would stop covering four medicines prescribed solely for weight loss. Other medically necessary uses require a new prior authorization, the plan's review before it pays. Requests for members younger than 21 retain a separate medical-necessity review.

Does Medicaid cover weight loss drugs for other conditions?

The documented condition matters. Diabetes treatment isn't on the weight-loss exclusion list. A drug's name alone doesn't establish whether a prescription falls within that exception.

California provides a concrete example. As of October 29, 2026, the day this article was written, Medi-Cal Rx's notice dated January 1, 2026 allows case-by-case requests for Wegovy for cardiovascular disease, meaning heart and blood-vessel disease, and for Zepbound for obstructive sleep apnea, repeated airway blockage during sleep. It also permits requests for Zepbound for obstructive sleep apnea, repeated airway blockage during sleep. These are reviews, rather than automatic payment. Our California GLP-1 law guide explains the separate state pricing law.

For someone prescribed tirzepatide, the useful coverage answer identifies the state, exact medicine, documented condition and current authorization rules.

What this means for a compounded prescription

A branded medicine's coverage doesn't establish payment for a compounded prescription. Compounding means a pharmacy prepares a medication for an individual prescription. The tirzepatide insurance guide explains why those prescriptions are generally paid out of pocket.

Through Promise, semaglutide and tirzepatide are dispensed by a licensed U.S. compounding pharmacy as compounded medications. Each is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that these preparations do not undergo its premarket review for safety, effectiveness or quality. A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed U.S. provider reviews every request; not everyone qualifies. The 1990 framework helps explain the coverage decision. The prescriber still makes the medical decision.